As a molecular target, further experiments are required to assess whether the level of induction in response to radiation can overcome the relatively high basal levels of exposure of CD166 on the vasculature to give the necessary specificity required for drug delivery, but the results suggest that radiosurgery could potentially be investigated in other contexts, such as prostate cancer, for further enhancement of CD166 expression and improved targeting specificity [12]. This evidence concerns the gene ALCAM and Familial prostate cancer.